Misconceptions about calcimimetics

被引：23
|
作者：
Nemeth, E. F. [1 ]
机构：
[1] NPS Pharmaceut Inc, Toronto, ON M5G 1L8, Canada
来源：
SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING | 2006年 / 1068卷
关键词：
calcimimetics; calcium receptor; allosteric modulators; drug discovery;
D O I：
10.1196/annals.1346.044
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Calcimimetics are ligands that activate the calcium receptor. Some are small molecules and of these, the most extensively studied are phenylalkylamines like cinacalcet. This compound is a positive allosteric modulator that selectively targets the parathyroid calcium receptor to inhibit the secretion of parathyroid hormone. Cinacalcet is the first calcimimetic compound to attain regulatory approval for the treatment of hyperparathyroidism resulting from end-stage renal disease. The discovery of calcimimetics and the receptor they act on are considered with the intent of extracting lessons relevant to medical research and the discovery of new drugs.
引用
收藏
页码：471 / 476
页数：6
相关论文
共 50 条
  • [31] Calcimimetics in the chronic kidney disease-mineral and bone disorder
    Bover, Jordi
    Aguilar, Armando
    Baas, Juan P.
    Reyes, Joselyne
    Lloret, Maria-J.
    Farre, Neus
    Olaya, Mayte
    Canal, Cristina
    Marco, Helena
    Andres, Enric
    Trinidad, Pedro
    Ballarin, Jose
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2009, 32 (02): : 108 - 121
  • [32] Regression of parathyroid hyperplasia by calcimimetics-025EFfact or illusion?
    Komaba, Hirotaka
    Fukagawa, Masafumi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (03) : 707 - 709
  • [33] New therapies: calcimimetics, phosphate binders and vitamin D receptor activators
    Jorge B. Cannata-Andía
    Minerva Rodriguez-García
    Pablo Román-García
    Diego Tuñón-le Poultel
    Francisco López-Hernández
    Diego Rodríguez-Puyol
    Pediatric Nephrology, 2010, 25 : 609 - 616
  • [34] Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both?
    Cannella, Giuseppe
    Messa, Piergiorgio
    JOURNAL OF NEPHROLOGY, 2006, 19 (04) : 399 - 402
  • [35] Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability
    Esteve Simo, Vicent
    Moreno-Guzman, Fatima
    Martinez Calvo, Gemma
    Fulquet Nicolas, Miquel
    Pou Potau, Monica
    Macias-Toro, Javier
    Duarte-Gallego, Veronica
    Saurina Sole, Anna
    Ramirez-de Arellano Serna, Manel
    NEFROLOGIA, 2015, 35 (04): : 403 - 409
  • [36] New therapies: calcimimetics, phosphate binders and vitamin D receptor activators
    Cannata-Andia, Jorge B.
    Rodriguez-Garcia, Minerva
    Roman-Garcia, Pablo
    Tunon-le Poultel, Diego
    Lopez-Hernandez, Francisco
    Rodriguez-Puyol, Diego
    PEDIATRIC NEPHROLOGY, 2010, 25 (04) : 609 - 616
  • [37] New potent calcimimetics: I. Discovery of a series of novel trisubstituted ureas
    Temal, Taoues
    Jary, Helene
    Auberval, Marielle
    Lively, Sarah
    Guedin, Denis
    Vevert, Jean-Paul
    Deprez, Pierre
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (08) : 2451 - 2454
  • [38] Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro
    Almaden, Yolanda
    Rodriguez, Marien
    Canalejo, Antonio
    Canadillas, Sagrario
    Canalejo, Rocio
    Martin, David
    Aguilera-Tejero, Escolastico
    Rodriguez, Mariano
    JOURNAL OF NEPHROLOGY, 2009, 22 (02) : 281 - 288
  • [39] Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease
    Hou, Yi-Chou
    Zheng, Cai-Mei
    Chiu, Hui-Wen
    Liu, Wen-Chih
    Lu, Kuo-Cheng
    Lu, Chien-Lin
    PHARMACEUTICALS, 2022, 15 (08)
  • [40] Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means
    Tilman B. Drüeke
    Pediatric Nephrology, 2005, 20 : 399 - 403
12345